Two pharmacies, a medical spa and a telehealth company voluntarily removed efficacy, safety and quality claims for compounded GLP-1 products after innovator companies filed challenges with the National Advertising Division.
Novo and Lilly are making progress in their uphill battle against ads for compounded GLP-1 products. (Shutterstock)
Key Takeaways
Novo Nordisk and Lilly increasingly are taking complaints about false and misleading claims for compounded GLP-1 products to the BBB National Programs’ National Advertising Division.
